Loading
Stiff, high-pressure tumours squeeze their own blood vessels shut, keeping drugs out. Softening them is a way in.
Desmoplastic tumours such as pancreatic cancer generate solid stress that collapses vessels; agents that reduce matrix stiffness (losartan, hyaluronidase, LOXL2 inhibitors) aim to reopen perfusion. PEGPH20, the furthest-advanced hyaluronidase, failed its phase 3 in pancreatic cancer, and losartan combinations remain investigational. The physics is well characterised; converting it into benefit has so far failed.
Reducing extracellular matrix content or stiffness lowers solid stress, decompresses vessels, and improves delivery of drugs and immune cells.
Query for this technology: (TITLE:"Targeting tumour mechanics and pressure" OR ABSTRACT:"Targeting tumour mechanics and pressure") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Targeting tumour mechanics and pressure, not a curated reading list.
Shares Radical oncology: what could change the war by 2035, Anti-angiogenic therapy, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag frontier.
Shares Radical oncology: what could change the war by 2035, Single-cell & spatial profiling, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag frontier.
Shares Radical oncology: what could change the war by 2035 and the tag frontier.
Shares Radical oncology: what could change the war by 2035 and the tag frontier.
Shares Radical oncology: what could change the war by 2035 and the tag frontier.
Shares Radical oncology: what could change the war by 2035 and the tag frontier.
Shares Radical oncology: what could change the war by 2035 and the tag frontier.
Shares FAP, Radical oncology: what could change the war by 2035, Fibroblast activation, desmoplasia & matrix stiffness, Pancreatic ductal adenocarcinoma and the tag frontier.